DNLI
Price
$13.67
Change
-$0.64 (-4.47%)
Updated
Jul 25 closing price
Capitalization
1.99B
3 days until earnings call
NTRB
Price
$8.81
Change
-$0.00 (-0.00%)
Updated
Jul 25 closing price
Capitalization
94.94M
65 days until earnings call
Interact to see
Advertisement

DNLI vs NTRB

Header iconDNLI vs NTRB Comparison
Open Charts DNLI vs NTRBBanner chart's image
Denali Therapeutics
Price$13.67
Change-$0.64 (-4.47%)
Volume$1.18M
Capitalization1.99B
Nutriband
Price$8.81
Change-$0.00 (-0.00%)
Volume$28
Capitalization94.94M
DNLI vs NTRB Comparison Chart in %
Loading...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NTRB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
DNLI vs. NTRB commentary
Jul 28, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DNLI is a StrongBuy and NTRB is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 28, 2025
Stock price -- (DNLI: $13.67 vs. NTRB: $8.53)
Brand notoriety: DNLI and NTRB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DNLI: 77% vs. NTRB: 56%
Market capitalization -- DNLI: $1.99B vs. NTRB: $94.94M
DNLI [@Biotechnology] is valued at $1.99B. NTRB’s [@Biotechnology] market capitalization is $94.94M. The market cap for tickers in the [@Biotechnology] industry ranges from $313.33B to $0. The average market capitalization across the [@Biotechnology] industry is $2.56B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DNLI’s FA Score shows that 0 FA rating(s) are green whileNTRB’s FA Score has 0 green FA rating(s).

  • DNLI’s FA Score: 0 green, 5 red.
  • NTRB’s FA Score: 0 green, 5 red.
According to our system of comparison, NTRB is a better buy in the long-term than DNLI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DNLI’s TA Score shows that 3 TA indicator(s) are bullish while NTRB’s TA Score has 3 bullish TA indicator(s).

  • DNLI’s TA Score: 3 bullish, 5 bearish.
  • NTRB’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, both DNLI and NTRB are a bad buy in the short-term.

Price Growth

DNLI (@Biotechnology) experienced а -2.36% price change this week, while NTRB (@Biotechnology) price change was +5.18% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.60%. For the same industry, the average monthly price growth was +17.32%, and the average quarterly price growth was +27.29%.

Reported Earning Dates

DNLI is expected to report earnings on Jul 31, 2025.

NTRB is expected to report earnings on Oct 01, 2025.

Industries' Descriptions

@Biotechnology (+7.60% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DNLI($1.99B) has a higher market cap than NTRB($94.9M). NTRB YTD gains are higher at: 81.104 vs. DNLI (-32.924). NTRB has higher annual earnings (EBITDA): -9.68M vs. DNLI (-505.16M). DNLI has more cash in the bank: 818M vs. NTRB (2.96M). NTRB has less debt than DNLI: NTRB (282K) vs DNLI (48.6M). NTRB has higher revenues than DNLI: NTRB (2.4M) vs DNLI (0).
DNLINTRBDNLI / NTRB
Capitalization1.99B94.9M2,093%
EBITDA-505.16M-9.68M5,218%
Gain YTD-32.92481.104-41%
P/E RatioN/AN/A-
Revenue02.4M-
Total Cash818M2.96M27,598%
Total Debt48.6M282K17,234%
FUNDAMENTALS RATINGS
DNLI vs NTRB: Fundamental Ratings
DNLI
NTRB
OUTLOOK RATING
1..100
5045
VALUATION
overvalued / fair valued / undervalued
1..100
93
Overvalued
76
Overvalued
PROFIT vs RISK RATING
1..100
10099
SMR RATING
1..100
9498
PRICE GROWTH RATING
1..100
8842
P/E GROWTH RATING
1..100
98100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NTRB's Valuation (76) in the null industry is in the same range as DNLI (93) in the Biotechnology industry. This means that NTRB’s stock grew similarly to DNLI’s over the last 12 months.

NTRB's Profit vs Risk Rating (99) in the null industry is in the same range as DNLI (100) in the Biotechnology industry. This means that NTRB’s stock grew similarly to DNLI’s over the last 12 months.

DNLI's SMR Rating (94) in the Biotechnology industry is in the same range as NTRB (98) in the null industry. This means that DNLI’s stock grew similarly to NTRB’s over the last 12 months.

NTRB's Price Growth Rating (42) in the null industry is somewhat better than the same rating for DNLI (88) in the Biotechnology industry. This means that NTRB’s stock grew somewhat faster than DNLI’s over the last 12 months.

DNLI's P/E Growth Rating (98) in the Biotechnology industry is in the same range as NTRB (100) in the null industry. This means that DNLI’s stock grew similarly to NTRB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DNLINTRB
RSI
ODDS (%)
N/A
Bearish Trend 4 days ago
85%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
76%
Bearish Trend 4 days ago
90%
Momentum
ODDS (%)
Bearish Trend 4 days ago
85%
Bullish Trend 4 days ago
82%
MACD
ODDS (%)
Bearish Trend 4 days ago
80%
Bullish Trend 4 days ago
81%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
83%
Bullish Trend 4 days ago
78%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
85%
Bullish Trend 4 days ago
82%
Advances
ODDS (%)
Bullish Trend 6 days ago
77%
Bullish Trend 7 days ago
82%
Declines
ODDS (%)
Bearish Trend 4 days ago
80%
Bearish Trend 18 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
83%
Bearish Trend 4 days ago
90%
Aroon
ODDS (%)
N/A
Bullish Trend 4 days ago
76%
View a ticker or compare two or three
Interact to see
Advertisement
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NTRB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
NHYDY6.300.04
+0.62%
Norsk Hydro ASA
BOVNF3.29N/A
N/A
Bioinvent International AB
HLPMF9.00N/A
N/A
HELLENiQ ENERGY Holdings SA
LOGN29.11N/A
N/A
Logansport Financial Corp.
LKSB12.25N/A
N/A
Lakeside Bancshares Inc LA

DNLI and

Correlation & Price change

A.I.dvisor indicates that over the last year, DNLI has been loosely correlated with BEAM. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if DNLI jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNLI
1D Price
Change %
DNLI100%
-4.47%
BEAM - DNLI
63%
Loosely correlated
+3.68%
NRIX - DNLI
62%
Loosely correlated
-0.09%
IDYA - DNLI
60%
Loosely correlated
-1.33%
RGNX - DNLI
58%
Loosely correlated
-1.86%
ARWR - DNLI
57%
Loosely correlated
-3.20%
More

NTRB and

Correlation & Price change

A.I.dvisor tells us that NTRB and STOK have been poorly correlated (+27% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that NTRB and STOK's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NTRB
1D Price
Change %
NTRB100%
-3.18%
STOK - NTRB
27%
Poorly correlated
-3.03%
ABSI - NTRB
26%
Poorly correlated
N/A
DNLI - NTRB
26%
Poorly correlated
-4.47%
REPL - NTRB
25%
Poorly correlated
+1.61%
SONN - NTRB
25%
Poorly correlated
-5.45%
More